Capricor Therapeutics, Inc. (CAPR) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow

Capricor Therapeutics presented at the 2026 MDA Clinical & Scientific Conference in March, showcasing its latest clinical and financial updates through a slide deck. The company reported a Q4 2025 earnings per share loss of $0.62, missing analyst estimates by $0.07, while revenue remained at $0.00, meeting expectations. No revenue generation was recorded, highlighting Capricor’s pre-commercial stage as it focuses on advancing its therapeutic pipeline, likely centered on rare diseases. The presentation aligns with the company’s strategy to leverage scientific conferences for investor and stakeholder engagement amid ongoing clinical trials. Financial performance underscores reliance on R&D funding, with no immediate revenue streams, emphasizing long-term growth potential over short-term profitability.